4 studies I’m watching today at #ESMO26

Mustafa Özdoğan, MD· @ozdogan_md · X·2026-10-25 19:20· 1 天前评分70

正文 · 原文

Presidential Symposium II (16:30 CET): KRAScendo 1, SAFFRON, CLARITY-Gastric 01 and HARMONi-GI1.
Which one are you waiting for?
I’ll post notes right after each LBA.
#Oncology

54 浏览 · 1 赞 · 1 转发 · 0 回复

会议摘要

2954TIPNCT07431281 NCT07431281 NCT07431281按 Oesophagogastric cancer 对上

CLARITY-Gastric 02: A randomised phase 3 study of sonesitatug vedotin (Sone-Ve) and capecitabine with or without rilvegostomig in Claudin18.2 positive (CLDN18.2+) advanced or metastatic gastric, gastroesophageal junction, or oesophageal ade

https://esmocongress.esmo.org

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

来源：Mustafa Özdoğan, MD · x.com